Polar Asset Management Partners Inc. Purchases 258,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS)

Polar Asset Management Partners Inc. raised its holdings in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 83.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 567,600 shares of the company's stock after purchasing an additional 258,000 shares during the quarter. Polar Asset Management Partners Inc. owned approximately 0.83% of COMPASS Pathways worth $3,576,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Logos Global Management LP raised its stake in shares of COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company's stock worth $7,001,000 after acquiring an additional 901,050 shares during the last quarter. Sio Capital Management LLC boosted its position in COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company's stock valued at $5,762,000 after buying an additional 621,222 shares during the last quarter. Acuta Capital Partners LLC acquired a new stake in shares of COMPASS Pathways in the 3rd quarter valued at $2,435,000. Walleye Capital LLC bought a new stake in shares of COMPASS Pathways during the third quarter worth $2,126,000. Finally, Renaissance Technologies LLC lifted its stake in shares of COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company's stock valued at $1,593,000 after acquiring an additional 247,500 shares during the period. Institutional investors and hedge funds own 46.19% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on CMPS. Cantor Fitzgerald reiterated an "overweight" rating on shares of COMPASS Pathways in a research report on Monday, September 9th. Royal Bank of Canada dropped their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. Maxim Group cut their price objective on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, November 1st. Finally, HC Wainwright reduced their price target on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $30.67.

Insider Transactions at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the sale, the insider now directly owns 6,905,774 shares of the company's stock, valued at $41,779,932.70. The trade was a 27.81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 4.25% of the stock is owned by insiders.

COMPASS Pathways Stock Down 1.1 %

Shares of NASDAQ:CMPS traded down $0.04 during trading on Thursday, hitting $4.10. 976,725 shares of the company's stock traded hands, compared to its average volume of 632,460. The company has a 50-day moving average price of $5.42 and a 200-day moving average price of $6.47. COMPASS Pathways plc has a 52 week low of $4.00 and a 52 week high of $12.75. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market cap of $280.18 million, a price-to-earnings ratio of -1.86 and a beta of 2.24.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.04. During the same quarter in the prior year, the company posted ($0.67) EPS. As a group, research analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.